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The Anticancer Agent Prodigiosin Is Not a Multidrug
Resistance Protein Substrate
Fatemeh Elahian, Bahareh Moghimi, Farideh Dinmohammadi, Mahsa Ghamghami,
Mehrdad Hamidi, and Seyed Abbas Mirzaei
The brilliant red pigments prodiginines are natural secondary metabolites that are produced by select species of
Gram-negative and Gram-positive bacteria. These molecules have received significant attention due to their
reported antibacterial, antifungal, immunosuppressive, and anticancer activities. In this study, a Serratia mar-
cescens SER1 strain was isolated and verified using 16s rDNA. The prodigiosin was purified using silica chro-
matography and was analyzed by 1H-NMR spectroscopy. The cell cytotoxic effects of the purified prodigiosin on
multiple drug resistant cell lines that overexpress MDR1, BCRP, or MRP2 pumps were analyzed. Prodigiosin
had nearly identical cytotoxic effects on the resistant cells in comparison to their parental lines. In agreement
with the same prodigiosin cytotoxicity, FACS analysis of prodigiosin accumulation and efflux in MDR over-
expressing cell lines also indicated that this pro-apoptotic agent operates independently of the presence of the
MDR1, BCRP, or MRP transporter and may be a potential treatment for malignant cancer cells that overexpress
multidrug resistance transporters.
Introduction
Prodiginines are natural red pigmented heterocyclic tri-pyrroles that appear at later phases of the bacterial
growth curve. Prodiginines consist of three broad structural
classes. The first group is the linear tripyrroles group,
which includes prodigiosin (isolated mainly from Serratia
marcescens, Serratia plymuthica, Hahella chejuensis, Pseudomo-
nas magnesiorubra, and Vibrio psychroerythreus) and un-
decylprodigiosin (isolated from Streptomyces longisporus
ruber, Streptoverticillium rubrireticuli, Actinomadura madurae,
Streptomyces coelicolor, and Saccharopolyspora sp.). The second
group is the macrocyclic group, which is characterized by
ring formation between pyrrole A and pyrrole C and in-
cludes cyclononylprodigiosin (isolated from Actinomadura
pelletieri and Actinomadura madurae). Finally, the third is the
cyclic group, which has a ring on pyrrole C and includes
cycloprodigiosin (isolated from Vibrio gazogenes, Alteromonas
rubra, and Pseudoalteromonas denitrificans) and butylcyclo-
heptylprodiginine (isolated from Saccharopolyspora sp and
Streptomyces coelicolor). Many of these alkaloids have been
examined for their antibacterial, antifungal, antiprotozoal,
antimalarial, algicidal, and insecticide characteristics (Ben-
nett and Bentley, 2000; Harris et al., 2004; Williamson et al.,
2006; Kim et al., 2008).
Although the physiological importance of these bioactive
secondary metabolites is not fully understood, they have
recently gained attention due to their immunosuppressive
and anticancer effects on myeloma, T-cell leukemia, Burkitt’s
lymphoma, and breast, colon, liver, and lung cancers, with
few adverse effects on noncancerous cells. Significant prog-
ress has been made in uncovering the mechanisms of these
anticancerous properties. The observed cellular effects in-
clude oxidative DNA damage (Elahian et al., 2012), the in-
duction of mitochondria-mediated apoptosis, inhibition of
phosphatases, and disruption of the pH gradient in various
cellular compartments, and DNA intercalation, cell cycle
arrest in late G1, and caspase activation (Montaner and
Perez-Tomas, 2003; Perez-Tomas et al., 2003; Francisco et al.,
2007; Williamson et al., 2007).
Multidrug resistance (MDR) is one of the major challenges
affecting the development of new chemotherapeutic agents.
MDR pumps on cancer cells can efflux a variety of traditional
anticancer drugs and reduce intracellular drug concentra-
tions, thereby leading to escape from cytotoxic effects of the
drugs. Recently, many attempts have been made to develop
new drugs that are not substrates for any of the three dif-
ferent MDR pumps (Gottesman, 2002). Preliminary studies
on breast cancer cells demonstrated that prodigiosin has
similar cytotoxicity on both MCF-7 and MCF7MX (mitox-
antrone resistant counterpart) cells. These data suggest that
prodigiosin may not be a substrate for the breast cancer re-
sistance protein (BCRP) pump (Soto-Cerrato et al., 2004). The
present study focused on the prodigiosin sensitivity of pa-
rental human gastric and ovarian cancer lines versus their
resistant counterparts that overexpress different MDR
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pumps. If prodiginines circumvent MDR-mediated resis-
tance, they will be good agents for cancer chemotherapy. In
addition, designing and discovering more potent anticancer
prodiginines that are not substrates for MDR pumps could
help to reduce the failure of chemotherapy regimens and
reduce cancer mortality.
Materials and Methods
Chemicals and media
Human cell culture media, trypsin, fetal bovine serum
(FBS), penicillin, and streptomycin were purchased from
Gibco (Grand Island, NY). MTT was obtained from Sigma–
Aldrich (Sigma–Aldrich, Deisenhofen, Germany). Superfine
Silica gel-60 powder, aluminum sheets of Silica TLC, Luria-
Bertani media, and Muller-Hinton media were provided by
Merck (Darmstadt, Germany). Primers were synthesized by
the Cinaclone Company (Tehran, Iran). All other chemicals
and solvents were of analytical grade and were purchased
from commercial sources in Iran.
Bacterial screening, identification, and prodigiosin
production
Soil samples were collected from the Zanjan University of
Medical Sciences yard, located in northwest Iran, during the
spring of 2011. The soil filtrates were cultured on either nu-
trient agar plates or selective media containing caprylate-
thallous (Starr et al., 1976). Red colonies were serially diluted
and subcultured on nutrient plates to achieve pure pigment
producer bacteria. The desired clones were genomic DNA
extracted and genotypically verified using 16 s rDNA am-
plification with universal primers (27F 5¢-AGATTTGATC
MTGGCTCAG-3¢ and 1492R 5¢-TACGGYTACCTTGTTACG
ACTT-3¢) and then sequencing (Andreazza et al., 2010;
Mirzaei et al., 2010). The sequences were blasted using the
NCBI BLAST Website and submitted to GenBank using the
NCBI Sequin software, version 11. Verified strains were
cultivated in 2% peanut media (2% w/v fine peanut powder
in 100mM potassium phosphate with a pH of 7.0) for pig-
ment production. A modified chromatographic approach
was developed for the purification steps (Giri et al., 2004; de
Araujo et al., 2010). The purified pigment was quantified
spectrophotometrically (TECAN, infinite-M200; Grodig,
Austria) by measuring the absorbance at 535 nm using a
standard curve and was structurally determined using 1H-
NMR (Bruker-400MH; Rheinstetler, Germany).
Cell culture
A2780RCIS (MRP1, 2 overexpressing human epithelial
ovarian cancer cell line), EPG85-257RNOV (BCRP over-
expressing human gastric carcinoma cell line), EPG85-
257RDB (MDR1 overexpressing human gastric carcinoma
cell line), and their parental lines were generously provided
by Professor Herman Lage (Molecular pathology depart-
ment, Charite Campus Mitte, Berlin, Deutschland). A2780
and EPG85-257 were cultured in RPMI-1640 media supple-
mented with 2mM L-glutamine, 10% (v/v) heat-inactivated
FBS, 50 IU/mL penicillin, and 50 mg/mL streptomycin at
37C in a humidified CO2 incubator. The media for the RCIS,
RNOV, and RDB resistant cell lines was also supple-
mented with 33.21 mM cisplatin, 0.386 mM mitoxantrone,
and 4.74 mM daunorubicin, respectively (Materna et al.,
2005; Lage et al., 2010).
Cell proliferation assay
To determine cell proliferation characteristics, 1000 cells
were plated into each well of 96-well plates in 200 mL of
growth medium. The culture medium was refreshed every
2 days. The growth rate evaluated during 7-day incubation
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. Formazan crystal production was
determined using the TECAN microplate reader after dis-
solving the crystals in dimethyl sulfoxide (DMSO) (Elahian
et al., 2009).
Cell cytotoxicity assay
The cells were seeded at 1000 cells per well in 96-well
plates and incubated at 37C for 24 h. A stock solution of
10mM prodigiosin in 10% DMSO was prepared and stored
in aliquots at - 20C. The stock was freshly diluted with
culture media before use and added to microplates at the
defined concentrations from 0–100 mM. Appropriate controls
containing DMSO were used to ensure that the solvent had
no intrinsic effect in the cytotoxicity assays at these concen-
trations. Cell viability was evaluated after a 5-day incubation
of the treated cells using MTT assay. IC50 was determined as
the concentration of drug that reduced 50% of the surviving
fraction of cells in each well as compared to the control. The
IC50 values of the cytotoxic drugs (cisplatin, daunorubicin,
and mitoxantrone) on the resistant cells and their corre-
sponding parental cells were also analyzed in the same way.
All experiments were performed three independent times in
triplicate (Elahian et al., 2010).
Detection of prodigiosin accumulation and efflux
FACS analysis of prodigiosin accumulation and efflux was
performed to determine whether this agent could be a sub-
strate for MDR transporters. To analyze drug transport, ap-
proximately 1· 105 cells of EPG85-257, EPG85-257RDB,
EPG85-257RNOV, A2780, or A2780RCIS were obtained by
trypsinization (van Hattum et al., 2002; Kowalski et al., 2005).
All cells were incubated in 1mM prodigiosin either with or
without a specific MDR pump inhibitor (Verapamil (10mM) as
the specific MDR1 inhibitor, novobiocin (200mM) as the spe-
cific BCRP inhibitor, or indomethacin (100mM) as the specific
multidrug resistance-associated protein [MRP] inhibitor) for
30min at 37C. Daunorubicin (1mM) was used as the positive
control for MDR1 and MRP transporters activity. Mitoxan-
trone (3mM) was applied as the positive control for BCRP
activity. Following adequate incubation periods, aliquots of
the cells were removed from each sample, washed twice with
ice-cold phosphate-buffered saline (PBS), and kept in PBS for
analysis of fluorescent drug uptake. Following the uptake
period and centrifugation, the supernatant was removed and
the cells were washed twice with ice-cold PBS and then the
cells were resuspended in drug-free medium either with or
without verapamil, indomethacin, or novobiocin and were
incubated for 1 h at 37C. Cells were then washed twice with
ice-cold PBS, placed in PBS at 4C, and kept in the dark
for analysis by flow cytometry (Marbeuf-Gueye et al., 2000;
Elahian et al., 2010).
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Flow cytometric analysis
The intracellular prodigiosin, daunorubicin, or mitoxan-
trone fluorescence intensities were determined using a BD
Biosciences FACSCalibureTM flow cytometer. Samples were
gated on forward/side scatter to exclude cell debris and
clumps. A total of 10,000 cells were measured per sample.
The autofluorescence of the cells was elucidated by mea-
suring the fluorescence of cells in PBS alone. Cells were
excited at 488 nm with an argon laser and the emission re-
corded via a 580 nm band-pass filter (FL2) for prodigiosin
and daunorubicin fluorescence, and 670 nm band-pass filter
(FL3) for mitoxantrone fluorescence. Flow cytometry data
were processed and analyzed using WinMDI version 2.8. All
assays were performed in at least three independent exper-
iments (Elahian et al., 2010).
Statistical analysis
All experiments were carried out in triplicate at least three
independent times and average values– standard errors
were reported. These data were analyzed using Student’s t-
test. p-values less than 0.05 were considered to be statistically
significant.
Results
Screening, purification, and prodigiosin identification
Samples from ecological niches such as soil and water
were cultured on nutrient or caprylate-thallous plates to
isolate pigment producing Serratia marcescens, and the best
prodigiosin producer was named S. marcescens SER1 and
verified using 16s rDNA amplification. The sequencing re-
sults were subjected to a homology search using BLAST
(ftp://ftp.ncbi.nih.gov), and the homology and the phylo-
genetic tree were identified. The new 1429 bp sequence was
submitted to GenBank under the accession number GI:
379327963. Fermentation at the optimal conditions yielded
approximately 5mg/mL crude prodigiosin after 2 days.
Pure, red, and needle-shaped crystals were obtained after
three sequential chromatographic steps. The pigments eluted
from the final step were found to be a homogeneous single
band by TLC. According to the Bear–Lambert equation, the
molar extinction coefficient of prodigiosin production was
calculated to be 0.1397mM- 1 cm - 1 (0.4311 L mg - 1 cm- 1), as
determined from the slope of the plot of DA535 versus pig-
ment concentration. The maximum UV absorbance was ob-
served at 535 nm, and the 1H-NMR spectroscopic data
verified the pigment to be prodigiosin (Fig. 1). The 1H-NMR
data were summarized as 1HNMR (CD2Cl2, 400MHz) d 6.5
(m, 7H, pyrrole-H, pyrrole-NH), 3.9 (s, 3H, OCH3), 2.25 (m,
2H, Ar-CH2), 1.8 (s, 3H, Ar-CH3), 0.85 (m, 9H, CH2-CH2-
CH2-CH3), which confirmed the structure of prodigiosin
(5[(3-methoxy-5-pyrrol-2-ylidene-pyrrol-2-ylidene)-methyl]-
2-methyl-3-pentyl-1Hpyrrole).
Growth characteristics of A2780 and EPG85-257 cells
The cells grew as a monolayer attached to the bottom of
the flask and appear to be small round clumps in shape. The
growth characteristics of A2780 and EPG85-257 lines and
their resistant counterparts were shown in Figure 2. The
difference between growth rates in parent versus resistant
FIG. 1. Prodigiosin structure according to 1H-NMR spec-
troscopy.
FIG. 2. Growth rate of A2780 (A), EPG85-257 (B) cells and
their resistant counterpart. Cells were seeded in 96-well
plates at 1000 cells/well in RPMI-1640 culture medium. Cells
were then counted using MTT assay during 7 days of seed-
ing. Data are mean– SE of three independent experiments
each in triplicate. The symbols ( ) and ( ) represent the
mean absorbance difference between parental and resistant
cells with p< 0.001 and p < 0.05, respectively.
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cells was highly statistically significant ( p< 0.05). Figure 2
also illustrates the point-by-point difference between A2780
and EPG85-257 cells and their resistant counterparts.
Effects of prodigiosin on parental cells
and their resistant counterparts’ proliferation
To investigate the effect of prodigiosin on cell survival,
parental and resistant A2780 and EPG85-257 cells were
treated with prodigiosin (0–100 mM). A dose–response curve
was fitted to our data, and the IC50 values were calculated
after 5 days of exposure (Fig. 3). Treatment with different
concentrations of cisplatin (0–100 mM), daunorubicin (0–
100 nM or 0–100 mM), or mitoxantrone (0–2000 nM) were also
performed, and the IC50 values were calculated after 5 days
of exposure. Despite significant difference in toxicity of cis-
platin, daunorubicin, and mitoxantrone ( p < 0.05), prodigio-
sin had nearly identical cytotoxicity on both parental and the
resistant cells ( p> 0.05) (Table 1).
Prodigiosin uptake in MDR cells
The cell samples used in this experiment included the
parental EPG85-257 (no MDR1, no BCRP), EPG85-257RDB
(high levels of MDR1), EPG85-257RNOV (high levels of
BCRP), A2780 (high levels of MRP1), and MRP1, 2 over-
expressing A2780RCIS cells. As expected, the EPG85-257 and
A2780 parent cells accumulated higher levels of mitoxan-
trone and daunorubicin after the uptake period than resis-
tant cells ( p< 0.001 and p< 0.05). EPG85-257RDB, EPG85-
257RNOV, and A2780RCIS cells showed high levels of
functionally active MDR1, BCRP, and MRP, as they accu-
mulated much less mitoxantrone and daunorubicin than
parental cells. By contrast, prodigiosin accumulated at simi-
lar levels in these resistant cells, compared with the parental
cells ( p> 0.05). These results indicated that prodigiosin is not
a substrate for MDR1, BCRP, and MRP (Fig. 4). Additional
data are given in Supplementary Figures S1 and S2 (Sup-
plementary Data are available online at www.liebertpub
.com/dna).
No prodigiosin transportation by MDR1,
BCRP, and MRP
EPG85-257 parent cells do not express any of MDR1 or
BCRP. Therefore, the specific MDR inhibitors like verapamil
or novobiocin did not inhibit the efflux for daunorubicin,
FIG. 3. Effects of prodigiosin on the survival of A2780 (A),
EPG85-257 (B) cells and their resistant counterpart. Cells
were cultured for 5 days with increasing doses of prodi-
giosin from 0 to 100 mM. Cell survival was measured by
MTT assay. The values represent the means of three inde-
pendent experiments performed in triplicate (Mean – SE).
p > 0.05 indicates that prodigiosin had nearly identical cy-
totoxicity on A2780 and EPG85-257 cells and their resistant
counterpart.
Table 1. IC50 Values of Prodigiosin and Anticancer Agents for the Normal
and Corresponding Resistant Cells
Prodigiosin Cisplatin Daunorubicin Mitoxantrone
IC50 – SE IC50 – SE IC50 – SE IC50 –SE
Cells (mM)a (mM) (mM) (mM)
A2780 8.92 – 0.272 1.97 – 0.084 ND ND
A2780RCIS 9.07 – 0.361 45.25– 1.985 ND ND
EPG85-257 8.45 – 0.216 ND 0.07 – 0.002 0.01 – 0.004
EPG85-257RDB 9.27 – 0.780 ND 9.06 – 0.136 ND
EPG85-257RNOV 9.08 – 0.136 ND ND 0.95 – 0.023
aDrug concentration required for 50% inhibition of cell growth after 5 days of drug exposure.
ND, not done.
Data represent the mean– standard error of three individual experiments.
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mitoxantrone, and prodigiosin, during the efflux period
(Fig. 5). However, EPG85-257RDB, EPG85-257RNOV,
A2780, or A2780RCIS cells showed high levels of func-
tionally active MDR1, BCRP, MRP1, or MRP2 and after
60min of the efflux period, the accumulation of the dau-
norubicin was enhanced in the presence of verapamil
( p < 0.01) or indomethacin ( p < 0.05 for A2780, and p < 0.001
for A2780RCIS) and the accumulation of mitoxantrone was
enhanced in the presence of novobiocin ( p < 0.05) (Figs. 5
and 6 and Table 2). In contrast, some decrease in fluores-
cence levels of prodigiosin was noted in the presence of
verapamil, novobiocin, or indomethacin after the efflux
period (Figs. 5 and 6 and Table 2). This decrease is not
statistically meaningful except in EPG parental cell. It seems
that the MDR pumps inhibitors compete with the cells’
uptake of daunorubicin, mitoxantrone, or prodigiosin and
lead to reduction of fluorescence after the efflux period
(Table 2 and Supplementary Figs. S1 and S2). These results
indicate that prodigiosin is not a substrate for MDR1, BCRP,
or MRP. Therefore, it is unlikely that the efficiency of this
antineoplastic agent will be affected by the presence of these
MDR transporters in tumor cells.
Discussion and Conclusion
Since its discovery in 1960 (Rapoport and Holden, 1962),
prodigiosin has been the subject of much anticancer re-
search. These promising studies provided valuable infor-
mation about prodigiosin and its mechanisms of action. For
example, it was shown that in addition to the anticancer
effects of prodigiosin, it can also circumvent drug resistance
by inducing apoptosis via p53-dependent or independent
mechanisms (Montaner et al., 2000). Activation of apoptotic
factors in both the cytoplasmic and the mitochondrial
pathway is an alternate method by which prodigiosin exerts
anticancer effects and escapes drug resistance (Campas
et al., 2003). Research has also shown that BCRP (a trans-
porter involved in MDR mainly belongs to the family of
ATP binding cassette (ABC) transporters) did not play a
role in prodigiosin resistance (Soto-Cerrato et al., 2004).
Among the various ABC-transporters, the following mem-
bers have been recognized as the most significant for clin-
ical MDR: the classical P-glycoprotein (P-gp, MDR1, or
ABCB1), the breast cancer resistance protein (BCRP,
ABCG2, MXR, or ABCP), and MRPs that represent the
MDR-associated proteins (Glavinas et al., 2004). The present
study was designed to prove and expand upon these
studies by investigating a variety of ABC transporters.
Different parental and resistant cell lines that overexpress
three main classes of ABC transporters were chosen, and
the cytotoxic effects of prodigiosin were investigated. These
FIG. 4. FACS analysis of accumulation of daunorubicin,
mitoxantrone, or prodigiosin in three individual experiments
in a panel of parental and their resistant cell lines. Values are
presented as the mean – SE. The symbols ( ) and ( ) repre-
sent the mean fluorescence difference between parental and
resistant cells with p < 0.001 and p < 0.05, respectively. Dnr,
daunorubicin; PG, prodigiosin; MX, mitoxantrone.
FIG. 5. Efflux analysis of
daunorubicin, mitoxantrone,
and prodigiosin in EPG85-
257 cells. The upper panel is
EPG85-257 parent cells and
the lower panel is EPG85-
257RDB and EPG85-
257RNOV resistant cells. No
drug (autofluorescence; solid
line), fluorescence levels after
60min of efflux in the ab-
sence (dashed line) or pres-
ence (dotted line) of the
inhibitors. Ver, verapamil;
Novo, novobiocin.
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experiments were also performed for daunorubicin and
mitoxantrone, the standard substrates for the ABC pumps.
Although the cytotoxic effects of prodigiosin were less than
those of cisplatin, daunorubicin, and mitoxantrone on the
parental cells, no meaningful differences were observed for
prodigiosin cytotoxicity on the resistant and parental cells.
However, cytotoxicity of the aforementioned ABC pumps’
substrates on their resistant lines dramatically differed from
FIG. 6. Efflux analysis of
daunorubicin and prodigiosin
in A2780 cells. The upper
panel is A2780 parent cells
and the lower panel is
A2780RCIS resistant cells. No
drug (autofluorescence; solid
line), fluorescence levels after
60min of efflux in the absence
(dashed line) or presence
(dotted line) of the inhibitor.
Indo, indomethacin.
Table 2. Mean Fluorescent Intensity of Prodigiosin, Daunorubicin, and Mitoxantrone in the Presence
and Absence of Specific Multidrug Resistance Inhibitors After Efflux Period
Mean fluorescent intensity (MFI) – SE
EPG85-257 EPG85-257RDB EPG85-257RNOV A2780 A2780RCIS
Prodigiosin 31.7 – 2.31 15.8 – 0.59 8.1 – 0.15 15.1 – 0.28 4.1 – 0.14
Prodigiosin +Ver 14.3 – 2.01 11.0 – 0.83 ND ND ND
Prodigiosin + Indo ND ND ND 13.3 – 0.62 3.4 – 0.15
Prodigiosin +Novo 7.4 – 0.53 ND 6.7 – 0.35 ND ND
Daunorubicin 134.1– 4.11 5.6 – 0.61 ND 50.4 – 0.62 24.7 – 1.64
Daunorubicin +Ver 66.4 – 3.98 11.4 – 0.95 ND ND ND
Daunorubicin + Indo ND ND ND 59.2 – 0.62 60.6 – 2.45
Mitoxantrone 185.5– 5.12 ND 59.9 – 2.51 ND ND
Mitoxantrone +Novo 111.9– 2.91 ND 117.5– 3.83 ND ND
ND, not done.
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the cytotoxicity on the parental cells. FACS analysis of ac-
cumulation and efflux of prodigiosin in MDR1, BCRP, or
MRP overexpressing cells also confirmed the results ob-
tained from cytotoxicity of prodigiosin on the parental and
their resistant cells. These data demonstrate that despite the
ABC pumps’ ability to effectively export daunorubicin or
mitoxantrone, they could not efflux prodigiosin out of the
human gastric carcinoma and human epithelial ovarian
cancer cells. Thus, prodigiosin is not an ABC transporter
substrate and could circumvent this mechanism of cancer
drug resistance in these cells. Therefore, chemical or bio-
logical modifications of prodigiosin could uncover more
potent derivatives, leading us closer to the ultimate goal of
finding improved chemotherapeutics for the treatment and
management of multidrug resistant cancers and reducing
cancer mortality. In conclusion, these data suggest that
prodigiosin is a novel potential apoptotic agent, which may
be effective irrespective of the presence of MDR transporter
molecules compared to routine anticancer agents like mi-
toxantrone, cisplatin, and daunorubicin.
Acknowledgments
The authors are grateful for financial support from Zanjan
University of Medical Sciences (grant No. 19/3-3/3426). We
also thank Professor Herman Lage (Charite Campus Mitte,
Berlin, Deutschland) for his valuable help.
Disclosure Statement
No competing financial interests exist.
References
Andreazza, R., Pieniz, S., Wolf, L., Lee, M.K., Camargo, F.A.,
and Okeke, B.C. (2010). Characterization of copper bioreduc-
tion and biosorption by a highly copper resistant bacterium
isolated from copper-contaminated vineyard soil. Sci Total
Environ 408, 1501–1507.
Bennett, J.W., and Bentley, R. (2000). Seeing red: the story of
prodigiosin. Adv Appl Microbiol 47, 1–32.
Campas C., Dalmau, M., Montaner, B., Barragan, M., Bellosillo,
B., Colomer, D., Pons, G., Perez-Tomas, R., and Gil, J. (2003).
Prodigiosin induces apoptosis of B and T cells from B-cell
chronic lymphocytic leukemia. Leukemia 17, 746–750.
de Araujo, H.W., Fukushima, K., and Takaki, G.M. (2010). Pro-
digiosin production by Serratia marcescens UCP 1549 using
renewable-resources as a low cost substrate. Molecules 15,
6931–6940.
Elahian, F., Kalalinia, F., and Behravan, J. (2009). Dex-
amethasone downregulates BCRP mRNA and protein ex-
pression in breast cancer cell lines. Oncol Res 18, 9–15.
Elahian, F., Kalalinia, F., and Behravan, J. (2010). Evaluation of
indomethacin and dexamethasone effects on BCRP-mediated
drug resistance in MCF-7 parental and resistant cell lines.
Drug Chem Toxicol 33, 113–119.
Elahian, F., Sepehrizadeh, Z., Moghimi, B., and Mirzaei, S.A.
(2012). Human cytochrome b5 reductase: structure, function,
and potential applications. Crit Rev Biotechnol. [Epub ahead
of print]; DOI: 10.3109/07388551.2012.732031.
Francisco, R., Perez-Tomas, R., Gimenez-Bonafe, P., Soto-
Cerrato, V., Gimenez-Xavier, P., and Ambrosio, S. (2007).
Mechanisms of prodigiosin cytotoxicity in human neuroblas-
toma cell lines. Eur J Pharmacol 572, 111–119.
Giri, A.V., Anandkumar, N., Muthukumaran, G., and Pen-
nathur, G. (2004). A novel medium for the enhanced cell
growth and production of prodigiosin from Serratia marces-
cens isolated from soil. BMC Microbiol 4, 11.
Glavinas, H., Krajcsi, P., Cserepes, J., and Sarkadi, B. (2004). The
role of ABC transporters in drug resistance, metabolism and
toxicity. Curr Drug Deliv 1, 27–42.
Gottesman, M.M. (2002). Mechanisms of cancer drug resistance.
Annu Rev Med 53, 615–627.
Harris, A.K., Williamson, N.R., Slater, H., Cox, A., Abbasi, S.,
Foulds, I., Simonsen, H.T., Leeper, F.J., and Salmond, G.P.
(2004). The Serratia gene cluster encoding biosynthesis of
the red antibiotic, prodigiosin, shows species- and strain-
dependent genome context variation. Microbiology 150,
3547–3560.
Kim, D., Kim, J.F., Yim, J.H., Kwon, S.K., Lee, C.H., and Lee,
H.K. (2008). Red to red - the marine bacterium Hahella che-
juensis and its product prodigiosin for mitigation of harmful
algal blooms. J Microbiol Biotechnol 18, 1621–1629.
Kowalski, P., Surowiak, P., and Lage, H. (2005). Reversal of
different drug-resistant phenotypes by an autocatalytic mul-
titarget multiribozyme directed against the transcripts of the
ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther
11, 508–522.
Lage, H., Duarte, N., Coburger, C., Hilgeroth, A., and Ferreira,
M.J.U. (2010). Antitumor activity of terpenoids against classi-
cal and atypical multidrug resistant cancer cells. Phytomedi-
cine 17, 441–448.
Marbeuf-Gueye, C., Salerno, M., Quidu, P., and Garnier-
Suillerot, A. (2000). Inhibition of the P-glycoprotein- and
multidrug resistance protein-mediated efflux of anthracyclines
and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol
17, 207–216.
Materna, V., Liedert, B., Thomale, J., and Lage, H. (2005). Pro-
tection of platinum–DNA adduct formation and reversal of
cisplatin resistance by anti-MRP2 hammerhead ribozymes in
human cancer cells. Int J Cancer 115, 393–402.
Mirzaei, S.A., Yazdi, M.T., and Sepehrizadeh, Z. (2010). Secre-
tory expression and purification of a soluble NADH cyto-
chrome b5 reductase enzyme from Mucor racemosus in Pichia
pastoris based on codon usage adaptation. Biotechnol Lett 32,
1705–1711.
Montaner, B., Navarro, S., Pique, M., Vilaseca, M., Martinell,
M., Giralt, E., Gil, J., and Perez-Tomas, R. (2000). Prodigiosin
from the supernatant of Serratia marcescens induces apo-
ptosis in haematopoietic cancer cell lines. Br J Pharmacol 131,
585–593.
Montaner, B., and Perez-Tomas, R. (2003). The prodigiosins: a
new family of anticancer drugs. Curr Cancer Drug Targets 3,
57–65.
Perez-Tomas, R., Montaner, B., Llagostera, E., and Soto-Cerrato,
V. (2003). The prodigiosins, proapoptotic drugs with anti-
cancer properties. Biochem Pharmacol 66, 1447–1452.
Rapoport, H.H., and Holden, K.G. (1962). The synthesis of
prodigiosin. J Am Chem Soc 84, 635.
Soto-Cerrato, V., Llagostera, E., Montaner, B., Scheffer, G.L., and
Perez-Tomas, R. (2004). Mitochondria-mediated apoptosis
operating irrespective of multidrug resistance in breast cancer
cells by the anticancer agent prodigiosin. Biochem Pharmacol
68, 1345–1352.
Starr, M.P., Grimont, P.A., Grimont, F., and Starr, P.B. (1976).
Caprylate-thallous agar medium for selectively isolating Ser-
ratia and its utility in the clinical laboratory. J Clin Microbiol 4,
270–276.
96 ELAHIAN ET AL.
van Hattum, A., Hoogsteen, I.J., Schlu¨per, H.M., Maliepaard, M.,
Scheffer, G.L., Scheper, R.J., Kohlhagen, G., Pommier, Y.,
Pinedo, H.M., and Boven, E. (2002). Induction of breast cancer
resistance protein by the camptothecin derivative DX-8951f is
associated with minor reduction of antitumour activity. Br J
Cancer 87, 665–672.
Williamson, N.R., Fineran, P.C., Gristwood, T., Chawrai, S.R.,
Leeper, F.J., and Salmond, G.P. (2007). Anticancer and im-
munosuppressive properties of bacterial prodiginines. Future
Microbiol 2, 605–618.
Williamson, N.R., Fineran, P.C., Leeper, F.J., and Salmond, G.P.
(2006). The biosynthesis and regulation of bacterial prodigi-
nines. Nat Rev Microbiol 4, 887–899.
Address correspondence to:
Seyed Abbas Mirzaei, PhD
Department of Pharmaceutical Biotechnology
School of Pharmacy
Zanjan University of Medical Sciences
Zanjan 45195-1338
Iran
E-mail: mirzaei@zums.ac.ir; dr_amirzaei@yahoo.com
Received for publication November 18, 2012; received in
revised form December 18, 2012; accepted January 5, 2013.
THE ANTICANCER AGENT PRODIGIOSIN 97
